Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ocular Therapeutix Inc OCUL

Healthcare
Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular... see more

Recent & Breaking News (NDAQ:OCUL)

Ocular Therapeutix(TM) Announces Positive Topline Phase 1 Data for AXPAXLI(TM) in Diabetic Retinopathy

GlobeNewswire 7 days ago

Ocular Therapeutix(TM) Strengthens Clinical Team with Appointment of Key Retinal Leaders

GlobeNewswire 9 days ago

Ocular Therapeutix(TM) Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO

GlobeNewswire 10 days ago

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics

GlobeNewswire April 9, 2024

Ocular Therapeutix(TM) Announces Positive Phase 2 PAXTRAVA(TM) Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

GlobeNewswire April 6, 2024

Ocular Therapeutix(TM) To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)

GlobeNewswire March 26, 2024

Ocular Therapeutix(TM) Reports Fourth Quarter and Full Year 2023 Results

GlobeNewswire March 11, 2024

Ocular Therapeutix(TM) to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024

GlobeNewswire March 5, 2024

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer

GlobeNewswire February 22, 2024

Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement

GlobeNewswire February 22, 2024

Ocular Therapeutix(TM) Announces Board of Directors and Leadership Updates

GlobeNewswire February 22, 2024

AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis

PR Newswire February 19, 2024

Ocular Therapeutix(TM) Appoints Steve Meyers to Chief Commercial Officer

GlobeNewswire February 15, 2024

Ocular Therapeutix(TM) Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI(TM) in Wet AMD

GlobeNewswire February 13, 2024

Ocular Therapeutix(TM) Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI(TM) in Wet AMD

GlobeNewswire January 25, 2024

Ocular Therapeutix(TM) Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

GlobeNewswire December 18, 2023

Ocular Therapeutix(TM) Announces Pricing of Public Offering of Common Stock

GlobeNewswire December 13, 2023

Ocular Therapeutix(TM) Announces Proposed Public Offering of Common Stock

GlobeNewswire December 13, 2023

Ocular Therapeutix(TM) to Present at Three Upcoming Investor Conferences

GlobeNewswire November 8, 2023

Ocular Therapeutix(TM) Provides Third Quarter 2023 Financial Results and Corporate Update

GlobeNewswire November 7, 2023